China: Ongoing Debate Over Patent Term Extensions for New Drug Hydrates

The scope of patent term extensions (PTE) for pharmaceutical inventions in China continues to generate significant discussion, particularly where a newly approved medicine is marketed as a hydrate or solvent complex rather than the exact compound claimed in the underlying patent. Recent commentary by Chinese intellectual property practitioners highlights the differing interpretations of China’s Patent Law and Patent Examination Guidelines, demonstrating that this remains an evolving area of pharmaceutical patent protection.

China’s Patent Term Extension Framework

Article 42 of the Chinese Patent Law allows patent term compensation for invention patents relating to new drugs that receive marketing authorisation in China. The purpose of the regime is to compensate patent holders for the time lost while new medicines undergo the lengthy regulatory approval process before they can be marketed. The extension is intended to restore part of the effective patent life that is consumed during regulatory review.

The framework is supported by three levels of legislation:

• the Patent Law;
• the Implementing Rules of the Patent Law; and
• the Patent Examination Guidelines.

While these instruments work together, their wording differs, creating uncertainty over how patent term extensions should be applied in certain situations.

The Central Issue

The current debate focuses on whether a compound patent should qualify for patent term compensation when the approved medicinal product is a hydrate.

One school of thought argues that a hydrate forms part of the same technical solution because it shares the core chemical framework of the patented compound. Under this interpretation, the compound patent should remain eligible for a patent term extension.

The opposing view is that hydrates and solvent complexes are distinct technical solutions. As a result, a patent claiming only the parent compound would not extend to the approved hydrate for the purposes of patent term compensation, meaning no extension should be granted.

Diverging Interpretations

The discussion has been prompted by differing interpretations of the Patent Examination Guidelines, which require the relevant patent claims to include the technical solution relating to the approved new drug.

A broader interpretation suggests that the requirement should include not only claims that are structurally identical to the approved medicine, but also claims covering its underlying chemical framework. Supporters of this approach argue that it is consistent with the legislative purpose of Article 42 of the Patent Law, namely compensating innovators for regulatory delays that reduce the effective period of patent protection.

By contrast, current examination practice by the China National Intellectual Property Administration (CNIPA) has generally adopted a narrower interpretation. Under this approach, if the approved medicine is a hydrate and the patent claims only the parent compound, the patent may not qualify for a patent term extension because the approved product is regarded as a different technical solution.

Potential Impact for Pharmaceutical Companies

The distinction is commercially significant. Patent term extensions can provide valuable additional exclusivity for innovative medicines, helping pharmaceutical companies recover research and development investment after lengthy regulatory approval procedures.

If the narrower interpretation continues to prevail, companies developing medicines that are ultimately approved in hydrate or solvent complex form could find that valuable compound patents are not eligible for patent term compensation, even where those patents protect the core technology underlying the approved product.

The differing interpretations also create uncertainty when developing patent filing strategies. Pharmaceutical innovators may wish to consider whether separate patent protection for hydrates, polymorphs, salts or other pharmaceutical forms should form part of a broader intellectual property strategy in China.

Looking Ahead

The authors of the underlying analysis argue that the Patent Examination Guidelines should be interpreted consistently with the broader legislative purpose of the Patent Law, ensuring that patent holders receive compensation where a patented invention forms the core technology of an approved new drug. Whether this broader interpretation will ultimately be adopted by the courts remains to be seen.

Until further judicial guidance emerges, patent applicants should closely monitor developments in both CNIPA examination practice and administrative litigation. Future decisions are likely to play an important role in defining the scope of patent term extensions for pharmaceutical inventions and may have a significant impact on patent protection strategies for innovative medicines in China.

Anjie Broad, China, a Transatlantic Law International Affiliated Firm.  

For further information or for any assistance please contact china@transatlanticlaw.com

Disclaimer: Transatlantic Law International Limited is a UK registered limited liability company providing international business and legal solutions through its own resources and the expertise of over 105 affiliated independent law firms in over 95 countries worldwide. This article is for background information only and provided in the context of the applicable law when published and does not constitute legal advice and cannot be relied on as such for any matter. Legal advice may be provided subject to the retention of Transatlantic Law International Limited’s services and its governing terms and conditions of service. Transatlantic Law International Limited, based at 84 Brook Street, London W1K 5EH, United Kingdom, is registered with Companies House, Reg Nr. 361484, with its registered address at 83 Cambridge Street, London SW1V 4PS, United Kingdom.